

WFS1 R685H — Wolframin

Arginine → Histidine at position 685 — SAME position as R685P (Atlas card flagship pathogenic-stabilising variant) and R685C. ClinVar Conflicting with broad spectrum — Wolfram, Cataract 41, DFNA6. AlphaMissense 0.12 (below threshold) — AM under-call. DynaMut2 $\Delta\Delta G$ -1.18 (substantial).

IDENTITY

Variant	R685H (p.Arginine685Histidine)
DNA change	c.2054G>A
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000215395
Amino acid change	Arginine (R) → Histidine (H) — long positively-charged amine replaced by smaller titratable aromatic.

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 685	89.94 HIGH CONFIDENCE
Domain	C-terminal lumenal domain (653-869)
Position context	C-terminal lumenal domain · position 685 (pLDDT 90). Same as R685P, R685C.
IDR flag	No — pLDDT well above 50 threshold

Position 685 same neighbors as R685P/R685C: THR686 (2.5 Å), ALA684 (2.5 Å — A684T/V/G), ASN682 (3.5 Å), MET683 (4.3 Å), GLN687 (4.4 Å — Q687H). R685H is the THIRD substitution at position 685 (with R685P, R685C). Partial charge reduction. $|\Delta\Delta G|$ 1.18 substantial; AM 0.12 under-call; multi-phenotype confirms.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.120am_class: **LBen** —
threshold > 0.564DYNAMUT2 $\Delta\Delta G$

PLDDT (ALPHAFOLD)

89.94

high confidence

-1.18 kcal/

mol

Destabilising · Job
177992507734

CLINICAL EVIDENCE

ClinVar classification

CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2025/08/09 00:00

Inheritance

Broad multi-phenotype.

WFS1 variant landscape

R685H is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- Wolfram syndrome 1
- Cataract 41
- Autosomal dominant nonsyndromic hearing loss 6 (DFNA6)

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G$ 2–4 → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable (AM under-call). $|\Delta\Delta G|$ 1.18 substantial. AlphaMissense 0.12 below threshold but THREE phenotypes + substantial $\Delta\Delta G$ confirm pathogenicity.

Mechanism: partial charge loss in the dense 684-688 cluster. Therapeutic: same cluster target as R685P, R685C, A684T/V/G, Q687H.

R685H is the THIRD substitution at position 685. The 684-688 cluster now contains 7+ variants — densest hub in the Atlas.

